Peer-reviewed veterinary case report
Comparing mitotane and trilostane for treating dog Cushing's disease
By Clemente, M et al.·Published in The Veterinary record·2007·Veterinary Teaching Hospital, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A group of dogs with pituitary-dependent hyperadrenocorticism (a condition causing excess cortisol) was treated with either mitotane or trilostane to see which worked better. The results showed that the mitotane treatment was effective for 89% of the dogs, but it had moderate side effects, and there were fewer relapses compared to the traditional treatment method. However, dogs treated with trilostane had a longer average survival time of about 900 days compared to 720 days for those on mitotane. This suggests that while both treatments can be effective, trilostane may offer a better long-term outcome.
People also search for: dog Cushing's disease treatment · mitotane vs trilostane for dogs · pituitary-dependent hyperadrenocorticism in dogs
Abstract
Forty-six dogs with pituitary-dependent hyperadrenocorticism were treated with mitotane by the non-selective adrenocorticolysis protocol and 40 were treated twice a day with trilostane. The treatment groups were compared by chi-squared tests, and survival data were analysed using Kaplan-Meier survival plots and a Cox proportional hazard method. The non-selective adrenocorticolysis protocol was very effective (89 per cent), its toxicity was moderate (24 per cent) and there were fewer recurrences (29 per cent) than reported with the classical selective adrenocorticolysis protocol (58 per cent). In a multivariate model, age and bodyweight at diagnosis were significantly negatively correlated with survival time. The median survival time of the dogs treated with trilostane twice a day (900 days) was longer (P=0.05) than that of the dogs treated with mitotane (720 days).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18083978/